Exforge/Exforge HCT, Novartis

Exforge/Exforge HCT (amlodipine/valsartan)

Global Sales 2012: $1.352 billion
U.S. Sales 2012: $358 million
Expiration Date: October 2014

When it was approved in the U.S. in 2007, Novartis' ($NVS) Exforge was the first hypertension drug to combine a calcium channel blocker (amlodipine) with an angiotensin receptor blocker (valsartan) into a single-dose drug, a combo that helped it hit blockbuster status.

Over the years, Novartis has had issues with the way it has marketed the drug. In 2010, it agreed to pay $422 million in civil and criminal penalties for allegedly paying kickbacks to doctors to persuade them to prescribe Exforge as well as blood pressure drugs Diovan and Tekturna. The company also received a DDMAC letter that year that said it had been using a misleading brochure for the drug.

Novartis will not take much of a hit in the U.S. for the loss of the patent. While Exforge remains a blockbuster, having sold about $1.4 billion worldwide, about three-fourths of those sales occur outside the U.S., where it sold only $358 million last year.  

For more:
Feds sue 'repeat offender' Novartis in Myfortic kickback scheme
FDA slaps Novartis for Facebook widget

-- Eric Palmer (email | Twitter)

Exforge/Exforge HCT, Novartis

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.